Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cholesterol drug and vitamin ease thyroid eye disease?

NCT ID NCT07400757

Disease control Sponsor: Taipei Veterans General Hospital, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking a statin (atorvastatin) and vitamin D can calm inflammation and reduce eye bulging in people with active thyroid eye disease. 120 adults will be randomly assigned to standard care alone, statin plus standard care, vitamin D plus standard care, or both supplements plus standard care for 24 weeks. The goal is to see if these simple, low-cost treatments can improve disease activity and eye symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atorvastatin (Lipitor) and vitamin D
What this could lead to
If it works, this could offer a simple, low-cost way to control active thyroid eye disease and reduce the need for stronger treatments.
What could go wrong
This is a small, early-phase trial (120 people) testing a repurposed drug and supplement. The effects may be modest or not better than standard care, and side effects like muscle pain or high blood sugar are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 20 years or older * Diagnosis of active thyroid eye disease with a Clinical Activity Score (CAS) of 3 or higher * Low-density lipoprotein cholesterol (LDL-C) level of 100 mg/dL or higher Exclusion Criteria: * Prior orbital radiotherapy or orbital surgery for thyroid eye disease * Use of statins or high-dose vitamin D supplementation (greater than 400 IU per day) within 3 months prior to enrollment * Pregnancy * Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m²

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves ophthalmopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease endocrine exophthalmos Graves Ophthalmopathy Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves ophthalmopathy Thyroid eye disease, ted

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, Taiwan, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.